Mohammed Kashani-Sabet, MD
Dermatology · San Francisco, CANPI 1629026174
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $1,953 of the $2,721 with a category attached, or 71.8%. E.r. Squibb & Sons, L.L.C. accounts for 77.2% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2021 at $2,060 and has fallen 96.6% since, to $70 in 2025.
Across 22 payments — averaging $123.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$2K
- Merck$209
- Seagen Inc.$107
- Envista Holdings Corporation$96
- Regeneron Healthcare Solutions, Inc.$77
- Novartis$30
- plus $102 from 4 others
What the payments were for
- Consulting fees$1,95372%
- Food & beverage$76828%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 8 | $2,100 |
| Merck | 5 | $209 |
| Seagen Inc. | 1 | $107 |
| Envista Holdings Corporation | 1 | $96 |
| Regeneron Healthcare Solutions, Inc. | 2 | $77 |
| Novartis | 1 | $30 |
| Kyowa Kirin, Inc. | 1 | $30 |
| Hologic Sales And Service, LLC | 1 | $29 |
| Array Biopharma Inc | 1 | $28 |
| GE HealthCare | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,721 in reported general payments places this provider in the 55th percentile of 1,875 dermatology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Triamcinolone Acetonide | 11 | $58 |
Paid to pharmacies, not to this prescriber.
Other dermatology in San Francisco
- Tina BhutaniSan Francisco$1.1M
- Sarina ElmariahSan Francisco$510K
- Timothy BergerSan Francisco$270K
- Marlys FassettSan Francisco$168K
- Caren CampbellSan Francisco$149K
- Kathleen WelshSan Francisco$149K
- Paul YamauchiSanta Monica$2.9M
- Jennifer SoungSanta Ana$2.8M
- Robert GreenbergLivermore$2.6M
- Neal BhatiaSan Diego$2.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.